Search clinical trials for: V504

Total 91 results

Merck Sharp & Dohme LLC

Completed

A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

Genital Warts | Cervical Cancers | Vulvar Cancers | Vaginal Cancers
Medical University Innsbruck

Recruiting

Evaluation of Tracheal Pressure During CPAP

Continuous Positive Airway Pressure | CPAP Ventilation

Austria
Merck Sharp & Dohme LLC

Active, not recruiting

Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)

Papillomavirus Infections

China
Merck Sharp & Dohme LLC

Withdrawn

Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)

Cervical Cancer | Condylomata Acuminata
Merck Sharp & Dohme LLC

Completed

Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts
Merck Sharp & Dohme LLC

Completed

A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)

Vulvar Cancer | Vaginal Cancer | HPV Infections | Cervical Cancers | Genital Lesions | PAP Test Abnormalities
Merck Sharp & Dohme LLC

Completed

A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).

Papillomavirus Infections
Massachusetts General Hospital
Dana-Farber Cancer Institute; Infinity Pharmaceuticals, Inc.

Terminated

IPI-504 in NSCLC Patients With ALK Translocations

Lung Cancer | Stage IV Lung Cancer | Stage IIIb Lung Cancer

United States
Infinity Pharmaceuticals, Inc.

Completed

Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)

Gastrointestinal Stromal Tumors | Soft Tissue Sarcomas

United States, Canada
Merck Sharp & Dohme LLC

Completed

Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)

Cervical Cancer | Genital Warts
Infinity Pharmaceuticals, Inc.

Withdrawn

Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Dedifferentiated Liposarcoma

United States
Infinity Pharmaceuticals, Inc.

Completed

Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma (IPi-504-01)

Multiple Myeloma

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts
Infinity Pharmaceuticals, Inc.

Terminated

A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
Infinity Pharmaceuticals, Inc.

Completed

Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

Lung Cancer

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)

Papillomavirus Infections

China
Merck Sharp & Dohme LLC

Completed

Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)

Papillomavirus Infections
Hutchison Medipharma Limited

Recruiting

Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients

Gastric Cancer | Esophagogastric Junction Disorder

China
Hutchison Medipharma Limited
Monash University; Sir Charles Gairdner Hospital; Austin Hospital, Melbourne...

Completed

Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors (HMPL-504)

Tumor

Australia
Merck Sharp & Dohme LLC

Completed

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

HPV Infections
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability Study of V501 in Japanese Boys (V501-200)

Condyloma Acuminata | Anogenital Human Papilloma Virus Infection

Japan
Merck Sharp & Dohme LLC

Completed

V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)

Cervical Cancer | Cervical Intraepithelial Neoplasia | Adenocarcinoma in Situ
Hutchison Medipharma Limited

Active, not recruiting

A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer

Lung Sarcomatoid Carcinoma

China
Hutchison Medipharma Limited

Completed

Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors (HMPL-504)

Tumors

China
Hutchison Medipharma Limited

Completed

A Food Effect Phase I Study of the Volitinib in Healthy Subjects (HMPL-504)

Food Effect | Health Subjects

China
NuMe Health
Pennington Biomedical Research Center

Completed

Pilot Study of the Effect of MN-504 Cobiotic Formulation on the Efficacy and Tolerability of Metformin

Type 2 Diabetes

United States
Merck Sharp & Dohme LLC

Completed

Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)

HIV-1 Infection

Germany, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)

Papillomavirus Infections | Human
AstraZeneca
SCRI Development Innovations, LLC

Completed

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Papillary Renal Cell Cancer

United States, Canada, United Kingdom, Spain
Merck Sharp & Dohme LLC

Completed

Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts
Mark Stein

Recruiting

Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer

Recurrent Prostate Cancer

United States
Merck Sharp & Dohme LLC

Active, not recruiting

V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)

Papillomavirus Infections

China
MedImmune LLC

Withdrawn

A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer

Breast Cancer

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)

Papillomavirus Infections

China
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)

Uterine Cervical Neoplasms | Papillomavirus Infections | Vulvar Neoplasms | Vaginal Neoplasms | Condylomata Acuminata | Adenocarcinoma in Situ

Vietnam
National Cancer Institute (NCI)

Terminated

Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer

Colorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage... and other conditions

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)

Genital Warts

China
Merck Sharp & Dohme LLC

Completed

Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)

Cervical Cancer | Genital Warts
Infinity Pharmaceuticals, Inc.

Completed

A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer (IPI-504-04)

Prostatic Neoplasms | Prostate Cancer | Cancer of the Prostate

United States
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)

Papillomavirus Infections

Japan
Merck Sharp & Dohme LLC

Completed

Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)

HPV 16 Infection
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

Papillomavirus Infections

United States, Belgium, Brazil, Colombia, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Spain, Taiwan, Thailand
Merck Sharp & Dohme LLC

Completed

A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)

Papillomavirus Infections
Hutchison Medipharma Limited

Recruiting

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC (SANOVO)

Non-small Cell Lung Cancer

China
Hutchison Medipharma Limited

Completed

A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers

Bioequivalence

China
Merck Sharp & Dohme LLC

Completed

An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)

HPV Infections
Infinity Pharmaceuticals, Inc.

Completed

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

United States, Hungary, Taiwan, Korea, Republic of, Russian Federation, Romania
Merck Sharp & Dohme LLC

Completed

Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Genital Warts | Human Papilloma Virus
Merck Sharp & Dohme LLC

Completed

A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)

Human Papillomavirus Infection

Search clinical trials for: V504

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations